We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Xtrackers FTSE Emerging Comprehensive Factor ETF | AMEX:DEMG | AMEX | Exchange Traded Fund |
Price Change | % Change | Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 23.865 | 0 | 01:00:00 |
RNS Number:5268S Deltex Medical Group PLC 26 November 2003 Deltex Medical Group plc ("Deltex Medical" / "Company") LAUNCH AND FIRST SALES OF PAEDIATRIC PROBE Chichester, UK - Deltex Medical (AIM LSE: DEMG) today announces the launch and first sales of a new probe, the pDP72, which enables its CardioQTM cardiac function and fluid status monitoring solution to be used in children. Chief Executive Andy Hill commented: "The launch in the UK of this new dedicated paediatric probe means that Deltex Medical is able to provide a minimally invasive, safe and effective means of monitoring cardiac performance and fluid status in this vulnerable group of young patients. "We are in discussions with a number of doctors interested in purchasing these probes and have already made sales to doctors at the Royal Alexandra Hospital for Sick Children in Brighton and to Nobles Hospital in the Isle of Man. These doctors will be able to ensure that paediatric patients undergoing surgery and those in intensive care can receive the benefits of haemodynamic optimisation previously only available to the adult population. "The Company is continuing to develop a range of probe solutions to meet specific clinical needs. The paediatric probe is designed for use on patients aged from two to sixteen years undergoing moderate and major surgery or critical care. The launch of this probe further demonstrates the considerable strength of the CardioQTM system to be adaptable to solutions tailored to different specialist applications." Enquiries Deltex Medical Group plc Nigel Keen, Chairman nigel.keen@deltexmedical.com 01243 774 837 Andy Hill, Chief Executive andy.hill@deltexmedical.com 01243 774 837 Ewan Phillips, Finance Director ewan.phillips@deltexmedical.com 01243 774 837 Notes for Editors Deltex Medical primarily develops, assembles and markets a cardiac function monitor and therapy guidance device, the CardioQTM ('CardioQTM'/'Monitor'). The CardioQTM incorporates the Company's proprietary software and a small diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is used for transmitting and receiving an ultra-sound ('Doppler') signal. By using this Doppler technology, the CardioQTM provides clinicians with the ability to haemodynamically optimise critically ill patients and those undergoing routine moderate to major surgery through the controlled administration of fluid and drugs. Haemodynamic optimisation has been scientifically proven to improve the speed and quality of patient recovery and reduce hospital stay. There are already over 1000 CardioQTMs currently in use in hospitals worldwide and distribution arrangements are in place in over 30 countries. In addition, there are currently more than 75 clinical publications on the use of the CardioQ TM which have repeatedly:- * validated the results of the Monitor against known standards for measuring cardiac output, demonstrating that the technology works * proved that the CardioQTM works in a wide range of surgical procedures * demonstrated that the Company's technology provides significant health and economic benefits by helping to reduce post-operative complications and length of hospital stays by an average of 30 to 40 per cent for a wide range of patients. This information is provided by RNS The company news service from the London Stock Exchange END PRLNKAKDNBDDQDB
1 Year Xtrackers FTSE Emerging ... Chart |
1 Month Xtrackers FTSE Emerging ... Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions